Literature DB >> 12534856

American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management guidelines: relevance to the geriatric practice.

Ali Ahmed1.   

Abstract

BACKGROUND: Heart failure (HF) is the only cardiovascular disease with increasing incidence and prevalence. Most HF patients are older adults. With the aging of the population and effective treatment of hypertension and coronary artery disease, the two major underlying causes of HF, the number of older Americans with HF is expected to rise significantly in the coming decades. HF is the number one hospital discharge diagnosis for older adults. It is one of the causes of frequent hospital readmissions, reflecting acute decompensation and compromised quality of life for patients and increased cost and resource use for the healthcare system. It is also associated with approximately 300,000 deaths annually, most in older adults. Advances in the management of HF in the past several decades have significantly decreased the mortality and morbidity associated with this condition. Randomized controlled trials have demonstrated the beneficial effects of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, beta-blockers, and spironolactone on survival and quality of life of HF patients, but there is evidence of underuse of evidence-based care for HF. Several national guidelines have been published since 1994 that recommended evidence-based evaluation and management of HF. In 1995, the American College of Cardiologists (ACC) and the American Heart Association (AHA) published their first HF guidelines that recommended left ventricular (LV) function evaluation for all patients presenting with HF and use of ACE inhibitors for all patients with LV systolic dysfunction (LVSD) unless contraindicated. The guidelines recommended the use of hydralazine and isosorbide dinitrate in patients who could not use ACE inhibitors. In addition, digoxin was recommended in patients with HF due to LVSD but not adequately responsive to ACE inhibitors and diuretics and in those with atrial fibrillation and rapid ventricular rates. Diuretic use was recommended for symptomatic patients with evidence of fluid overload. Use of anticoagulation was restricted to patients with atrial fibrillation or to those with a history of systemic or pulmonary embolism. Beta-blockers were reserved for HF patients after acute myocardial infarctions. Recent advances in the management of HF called for a revision of the guidelines.
PURPOSE: The purpose of revising the 1995 ACC/AHA guidelines was to incorporate recent advances in pharmacological and nonpharmacological approaches to HF treatment and to assist physicians in clinical decision-making in the management of HF.
METHODS: The ACC/AHA invited representatives from the American College of Chest Physicians, the Heart Failure Society of America, the International Society for Heart and Lung Transplantation, the American Academy of Family Physicians, and the American College of Physicians-American Society of Internal Medicine to participate in the preparation of the guidelines. The writing committee searched pertinent medical literature in English using computerized databases such as MEDLINE and EMBASE and manually searching the bibliographies of the selected articles. The writing committee classified HF into four stages, including patients who are at high risk for developing HF. According to this new classification, Stage A and B represent asymptomatic patients, the former at high risk for developing HF but no structural disorder, the latter with structural disorders of the heart. Stage C encompasses patients with underlying structural heart disorders who are symptomatic, either currently or in the past. Stage D includes end-stage HF patients. This new classification is intended to complement the New York Heart Association (NYHA) functional classification of HF into Class I (asymptomatic), Class II (symptomatic on less than ordinary exertion), Class III (symptomatic on ordinary exertion), and Class IV (symptomatic at rest).
RESULTS: The recommendations are categorized into those for evaluation and management.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12534856     DOI: 10.1034/j.1601-5215.2002.51020.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  12 in total

1.  Azygos Vein Aneurysm Mimicking a Mediastinal Mass.

Authors:  Cornel Savu; Alexandru Melinte; Irina Balescu; Nicolae Bacalbasa
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Ageing-related cardiomyocyte functional decline is sex and angiotensin II dependent.

Authors:  Kimberley M Mellor; Claire L Curl; Chanchal Chandramouli; Thierry Pedrazzini; Igor R Wendt; Lea M D Delbridge
Journal:  Age (Dordr)       Date:  2014-02-25

3.  Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces.

Authors:  Douglas A Simonetto; Hui-yin Yang; Meng Yin; Thiago M de Assuncao; Jung Hee Kwon; Moira Hilscher; Shuchong Pan; Liu Yang; Yan Bi; Arthur Beyder; Sheng Cao; Robert D Simari; Richard Ehman; Patrick S Kamath; Vijay H Shah
Journal:  Hepatology       Date:  2015-01-05       Impact factor: 17.425

4.  Chronic heart failure in older adults.

Authors:  Ali Ahmed
Journal:  Med Clin North Am       Date:  2011-05       Impact factor: 5.456

5.  Impact of spironolactone on endothelial function in patients with single ventricle heart.

Authors:  William T Mahle; Alicia Wang; Arshed A Quyyumi; Michael E McConnell; Wendy M Book
Journal:  Congenit Heart Dis       Date:  2009 Jan-Feb       Impact factor: 2.007

Review 6.  Medication management of chronic heart failure in older adults.

Authors:  Kannayiram Alagiakrishnan; Maciej Banach; Linda G Jones; Ali Ahmed; Wilbert S Aronow
Journal:  Drugs Aging       Date:  2013-10       Impact factor: 3.923

7.  Falls in the general elderly population: a 3- and 6- year prospective study of risk factors using data from the longitudinal population study 'Good ageing in Skane'.

Authors:  Magnus Stenhagen; Henrik Ekström; Eva Nordell; Sölve Elmståhl
Journal:  BMC Geriatr       Date:  2013-08-07       Impact factor: 3.921

8.  Effects of bisoprolol in combination with trimetazidine on the treatment of heart failure and concomitant chronic obstructive pulmonary disease.

Authors:  Yuanyuan Ke; Dingli Xu; Minxiong Li; Zenglong Wu; Yongpeng Huang
Journal:  Pak J Med Sci       Date:  2016 Sep-Oct       Impact factor: 1.088

9.  A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers.

Authors:  Seyed Ali Sadjadi; James I McMillan; Navin Jaipaul; Patricia Blakely; Su Su Hline
Journal:  Ther Clin Risk Manag       Date:  2009-07-12       Impact factor: 2.423

10.  Association between neutrophilic granulocyte percentage and depression in hospitalized patients with heart failure.

Authors:  Shuo Pan; Zhong-Wei Liu; Ying Lv; Wen-Qian Song; Xun Ma; Gong-Chang Guan; Yong Zhang; Shun-Ming Zhu; Fu-Qiang Liu; Bo Liu; Zhi-Guo Tang; Jun-Kui Wang
Journal:  BMC Psychiatry       Date:  2016-12-13       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.